U.C. Berkeley and the Broad Institute are fighting to control the patents on the revolutionary gene-editing technology. But there's a lot more at stake than just who gets the credit and licensing fees.

The International Summit on Human Gene Editing drew a distinction between editing an individual's body cells and editing germline cells that would pass changes to future generations. Does that make sense?